Assembly Biosciences, Inc. (ASMB) 

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Show less

Over the last 12 months, insiders at Assembly Biosciences, Inc. have bought $793,544 and sold $137,402 worth of Assembly Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Assembly Biosciences, Inc. have bought $793,544 and sold $377,807 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Schornstein Alexander (10 percent owner) — $793,364. GILEAD SCIENCES, INC. (10 percent owner) — $718.

The last purchase of 179,500 shares for transaction amount of $180 was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑06‑17.